Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?
 

Increased capsaicin-induced secondary hyperalgesia in patients with MCS

Saturday 12 February 2011

Slightly AliveFrom PubMed:

 

Clin J Pain. 2011 Feb;27(2):156-62.

Increased capsaicin-induced secondary hyperalgesia in patients with multiple chemical sensitivity.

Holst H, Arendt-Nielsen L, Mosbech H, Elberling J.

Danish Research Centre for Chemical Sensitivities, Gentofte Hospital University of Copenhagen.

Abstract

OBJECTIVE: the underlying cause of pathophysiological mechanisms triggering multiple chemical sensitivity (MCS) remains disputed. Recently, alterations in the central nervous system, for example, central sensitization, similar to various chronic pain disorders, have been suggested. Capsaicin is used in experimental pain models to provoke peripheral and central sensitization. In patients with symptoms elicited by odorous chemicals capsaicin-induced secondary hyperalgesia and temporal summation were assessed as markers for abnormal central nociceptive processing together with neurogenic inflammation (flare).

METHODS: sixteen patients fulfilling Cullen criteria for MCS and 15 eczema patients with airway symptoms induced by odorous chemicals (EC) were compared with 29 age-matched healthy controls. Participants underwent 2 intradermal injection of capsaicin (3.3 mM and 33 mM). Measurements included pain intensity, flare, pinprick hyperalgesia, temporal summation, and McGill Pain Questionnaire score.

RESULTS: no difference was found in the flare area between the groups. The capsaicin-evoked pain intensity was higher in MCS patients compared with controls (P<0.01, 33 mM). The area of secondary hyperalgesia was larger in both the patient groups compared with controls (P<0.05) at both capsaicin concentrations. Temporal summation was increased in MCS patients compared with controls (P<0.01). Further, in patients with comorbidity of fibromyalgia, pain and chronic fatigue, pain continued after end stimulation, and the stimulus response function was enhanced compared with patients without comorbidity, and significant to controls (P<0.05).

CONCLUSION: this is the first study to show facilitated pain processing in MCS and EC patients with the most abnormal responses in MCS.

PMID: 21268302 [PubMed - in process]

 

The above originally appeared here.

 


Arrow right

More Multiple Chemical Sensitivity news

 


 

blog comments powered by Disqus
Previous Previous Page